drugset / Trial / NCT05030155
Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)
Phase 3
Completed
102 enrolled
Assistance Publique - Hôpitaux de Paris
French Vasculitis Study Group · collabURC-CIC Paris Descartes Necker Cochin · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to compare mepolizumab-based regimen to conventional therapeutic strategy for remission induction in patients with Eosinophilic Granulomatosis with Polyangiitis.
Timeline
- Start
- 2022-05-30
- Primary completion
- 2025-02-21
- Completion
- 2025-09-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Azathioprine | Small molecule | 1 mg/kg | — |
| Comparator | Cyclophosphamide | Other / unclassified | — | — |
| Subject | Mepolizumab | Monoclonal antibody | 300 mg | Subcutaneous |